Business
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
LEXINGTON, Mass., March 10, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic collaboration with Zydus Lifesciences Ltd.
About this update from Zydus Lifesciences Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1694,"height":353,"url":"https://media.zenfs.com/en/business-wire.com/af0fc235b6f864bb18a6b55ba989f92b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eaIxih8OhBBhmdJ30KtDTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/af0fc235b6f864bb18a6b55ba989f92b","width":960,"height":200},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/hZBg3qzb8wsq5gTnxDrNXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/af0fc235b6f864bb18a6b55ba989f92b","width":1200,"height":250}},"lazy":false},{"type":"text","content":"Work orders for key CMC and production activities activate first contingent payment as global demand expands across clinical and paid compassionate access programs","length":163,"tagName":"p"},{"type":"text","content":"LEXINGTON, Mass., March 10, 2026--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic collaboration with Zydus Lifesciences Ltd.","length":281,"tagName":"p"},{"type":"text","content":"The payment was triggered by contracted work orders for critical chemistry, manufacturing and controls (CMC) and production activities related to botensilimab (BOT) and balstilimab (BAL). These activities will allow Zydus to perform the initiation of its commercial supply of Agenus’ lead programs. They also include additional manufacturing work to satisfy regulatory requirements for BLA and MAA readiness, to build upon existing inventory in anticipation of increasing demand across clinical development programs, authorized early access pathways, and to support potential global commercialization.","length":601,"tagName":"p"},{"type":"text","content":"This milestone marks the first operational activities between Agenus and Zylidac Bio LLC, the U.S.-based biologics manufacturing subsidiary of Zydus Life Sciences.","length":163,"tagName":"p"},{"type":"text","content":""This milestone reflects our commitment to progressing BOT and BAL to regulatory approval readiness, and to support our ongoing clinical development and paid compassionate access program ne...